BioLife BLFS Stock
BioLife Price Chart
BioLife BLFS Financial and Trading Overview
| BioLife stock price | 24.79 USD |
| Previous Close | 26.04 USD |
| Open | 26.05 USD |
| Bid | 18.48 USD x 200 |
| Ask | 31.92 USD x 200 |
| Day's Range | 24.88 - 26.31 USD |
| 52 Week Range | 17.86 - 29.62 USD |
| Volume | 645.96K USD |
| Avg. Volume | 537.24K USD |
| Market Cap | 1.22B USD |
| Beta (5Y Monthly) | 1.971 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.24 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.3 USD |
BLFS Valuation Measures
| Enterprise Value | 1.15B USD |
| Trailing P/E | N/A |
| Forward P/E | 85.86207 |
| PEG Ratio (5 yr expected) | 15.09 |
| Price/Sales (ttm) | 11.966846 |
| Price/Book (mrq) | 3.266002 |
| Enterprise Value/Revenue | 11.316 |
| Enterprise Value/EBITDA | 266.237 |
Trading Information
BioLife Stock Price History
| Beta (5Y Monthly) | 1.971 |
| 52-Week Change | 21.91% |
| S&P500 52-Week Change | 24.48% |
| 52 Week High | 29.62 USD |
| 52 Week Low | 17.86 USD |
| 50-Day Moving Average | 23.28 USD |
| 200-Day Moving Average | 23.98 USD |
BLFS Share Statistics
| Avg. Volume (3 month) | 537.24K USD |
| Avg. Daily Volume (10-Days) | 681.04K USD |
| Shares Outstanding | 48.86M |
| Float | 42.73M |
| Short Ratio | 6.75 |
| % Held by Insiders | 2.38% |
| % Held by Institutions | 104.50% |
| Shares Short | 3.98M |
| Short % of Float | 12.74% |
| Short % of Shares Outstanding | 8.14% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:14 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -2.91% |
| Operating Margin (ttm) | 0.098% |
| Gross Margin | 63.75% |
| EBITDA Margin | 4.25% |
Management Effectiveness
| Return on Assets (ttm) | -0.086% |
| Return on Equity (ttm) | -3.094% |
Income Statement
| Revenue (ttm) | 101.66M USD |
| Revenue Per Share (ttm) | 2.11 USD |
| Quarterly Revenue Growth (yoy) | 24.69% |
| Gross Profit (ttm) | 64.81M USD |
| EBITDA | 4.32M USD |
| Net Income Avi to Common (ttm) | -11215000 USD |
| Diluted EPS (ttm) | -0.24 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 81M USD |
| Total Cash Per Share (mrq) | 1.66 USD |
| Total Debt (mrq) | 14.86M USD |
| Total Debt/Equity (mrq) | 3.99 USD |
| Current Ratio (mrq) | 7.299 |
| Book Value Per Share (mrq) | 7.624 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 17.9M USD |
| Levered Free Cash Flow (ttm) | 6.39M USD |
Profile of BioLife
| Country | United States |
| State | WA |
| City | Bothell |
| Address | 3303 Monte Villa Parkway |
| ZIP | 98021 |
| Phone | 425 402 1400 |
| Website | https://www.biolifesolutions.com |
| Industry | Medical Instruments & Supplies |
| Sector(s) | Healthcare |
| Full Time Employees | 155 |
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Q&A For BioLife Stock
What is a current BLFS stock price?
BioLife BLFS stock price today per share is 24.79 USD.
How to purchase BioLife stock?
You can buy BLFS shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BioLife?
The stock symbol or ticker of BioLife is BLFS.
Which industry does the BioLife company belong to?
The BioLife industry is Medical Instruments & Supplies.
How many shares does BioLife have in circulation?
The max supply of BioLife shares is 48.86M.
What is BioLife Price to Earnings Ratio (PE Ratio)?
BioLife PE Ratio is now.
What was BioLife earnings per share over the trailing 12 months (TTM)?
BioLife EPS is -0.24 USD over the trailing 12 months.
Which sector does the BioLife company belong to?
The BioLife sector is Healthcare.
BioLife BLFS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
US Tech Capital Market Composite
RCMP
US
|
146.53 USD — |
-0.75
|
— — | 144.14 USD — | 148.72 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
31560.2 USD — |
-2.21
|
— — | 31469.2 USD — | 31924.72 USD — | — - | — — |
- {{ link.label }} {{link}}